• An oral drug called danegaptide showed early biological activity in people with non-proliferative diabetic retinopathy.
  • In a small study of 24 patients, 55% showed signs including reduced retinal leakage or fluid.
  • This was an early-stage trial designed mainly to assess safety, so larger controlled trials are needed before we know whether the drug preserves vision.

A tablet that targets the blood vessels damaged in diabetic retinopathy has shown encouraging early results in people with diabetes.

Researchers at Trinity College Dublin and Breye Therapeutics tested an experimental drug called danegaptide, which is taken orally rather than injected into the eye.

The research focused on non-proliferative diabetic retinopathy, an earlier stage of diabetic eye disease in which high blood glucose damages small blood vessels in the retina.

In laboratory models, danegaptide reduced leakage from retinal blood vessels, protected the inner blood-retina barrier and reduced retinal swelling.

Researchers then tested the treatment in 24 people with non-proliferative diabetic retinopathy and mild centre-involved macular oedema.

The treatment was reported to be safe and well tolerated in this early study.

Around 55% of participants also showed what the researchers describe as early biological activity.

That included reductions in retinal leakage, decreased thickness in the centre of the retina and, in some participants, resolution of fluid-filled cysts inside the retina.

That is potentially important because fluid leaking into the macula can lead to diabetic macular oedema and maculopathy.

Current treatment for more advanced diabetic retinal disease can include injections directly into the eye.

Those injections, including anti-VEGF treatment, can be highly effective, but they usually need to be given repeatedly and require regular hospital appointments.

An oral treatment that could intervene earlier would therefore be attractive.

But this study is nowhere near proving that a tablet can replace eye injections.

Twenty-four patients is a very small trial.

The main purpose of phase 1 studies is generally to assess safety, dose and biological activity rather than prove that a treatment prevents sight loss.

There is also a major difference between making a retinal scan look better and showing that patients actually maintain better vision over several years.

That will require much larger randomised trials.

The researchers now plan to move into phase 2 testing, with a larger controlled study expected to investigate whether the promising biological changes translate into meaningful clinical benefit.

For people living with type 1 diabetes or type 2 diabetes in the UK, nothing changes yet.

The most effective approach remains detecting retinal changes before they affect sight.

That means attending diabetic eye screening when invited and not assuming that normal vision means the retina is healthy.

Retinopathy can develop without noticeable symptoms.

Managing HbA1c, blood pressure and other cardiovascular risk factors also remains central to reducing progression.

People with diabetes should also keep up with wider screening for diabetes complications rather than waiting until symptoms develop.

Danegaptide is therefore an interesting treatment to watch, not something patients can currently request.

If larger trials work, however, the idea of treating early diabetic retinal disease with a tablet rather than waiting until injections become necessary could represent a meaningful change in care.

Study: Science Translational Medicine – danegaptide in diabetic retinopathy

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.